U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07256964) titled 'Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer' on Nov. 19.
Brief Summary: This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for patients with triple-negative breast cancer.
Study Start Date: Nov. 26
Study Type: INTERVENTIONAL
Condition:
TNBC - Triple-Negative Breast Cancer
Intervention:
DRUG: Toripalimab
Toripalimab 240mg every cycle
DRUG: PCb-EC
Albumi...